Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Deferred Tax (2023 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $73.4 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 99.13% to $73.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.4 million through Dec 2025, up 99.13% year-over-year, with the annual reading at $73.4 million for FY2025, 99.13% up from the prior year.
  • Long-Term Deferred Tax hit $73.4 million in Q4 2025 for ARS Pharmaceuticals, up from $36.9 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $73.4 million in Q4 2025 to a low of $29.0 million in Q4 2023.
  • Historically, Long-Term Deferred Tax has averaged $46.4 million across 3 years, with a median of $36.9 million in 2024.
  • Biggest five-year swings in Long-Term Deferred Tax: increased 26.92% in 2024 and later surged 99.13% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $29.0 million in 2023, then increased by 26.92% to $36.9 million in 2024, then soared by 99.13% to $73.4 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for SPRY at $73.4 million in Q4 2025, $36.9 million in Q4 2024, and $29.0 million in Q4 2023.